SNDX-5613
SNDX-5613 is a potent and specific inhibitor of Menin-MLL (Ki of 0.149 nM and a cell based IC50 of 10-20 nM) . SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. (In Vivo) :Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.
Product Specifications
CAS Number
2169919-21-3
Purity
>98% (HPLC)
Solubility
DMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)
Smiles
O=C (C1=CC (F) =CC=C1OC2=CN=CN=C2N3CC4 (C3) CCN (CC4) C[C@H]5CC[C@@H] (CC5) NS (=O) (CC) =O) N (C (C) C) CC
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.82
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-52850R-BF350 100 µL
KLF4 Recombinant Antibody, AbBy Fluor™ 350 Conjugated
Sign In for Pricing
View Details 
